Call us now

08071779111

Send Inquiry

Request To Call Back

Tacrolimus Capsules IP

Name: Tacrolimus Capsules IP
Brand: GLOBMED INDIA

Get a Price/Quote

MOQ : 10 Packs

Tacrolimus Capsules IP Specification

Brand Name
TAKFA 0.5

Life Span
24 months (approximate)

Origin of Medicine
India

Pacakaging (Quantity Per Box)
5 x 10 capsules per box

Dosage Form
Capsules

Packaging Type
Blister pack

Indication
Prophylaxis of organ rejection in kidney, liver, or heart transplant recipients

Salt Composition
Tacrolimus

Drug Type
Allopathic

Ingredients
Tacrolimus IP

Physical Form
Capsule

Function
Immunosuppressant

Recommended For
Prevention of organ transplant rejection

Dosage
As directed by physician, commonly 0.5 mg per capsule

Dosage Guidelines
Take orally as prescribed, do not exceed recommended dose

Suitable For
Adults

Quantity
10 capsules per strip

Storage Instructions
Store below 25C, protect from moisture and light

Prescription Required
Yes

Strength
0.5 mg

Color of Capsule
White

Side Effects
Possible side effects include increased risk of infection, kidney problems, and hypertension

Warning
Should be used only under medical supervision

Marketed By
Intas Pharmaceuticals Ltd.

Administration Route
Oral

Tacrolimus Capsules IP Trade Information

Minimum Order Quantity
10 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
1000 Packs Per Month

Delivery Time
2-5 Days

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

Tacrolimus Capsules IP About

TAKFA 0.5 Tacrolimus Capsules IP, marketed by Intas Pharmaceuticals Ltd., is a highly recommended immunosuppressant designed for the prevention of organ transplant rejection. Each venerable white capsule contains 0.5 mg of impeccable Tacrolimus IP, ensuring extraordinary efficacy in safeguarding transplanted kidneys, liver, or heart. Prescription is required, as it should be administered only under medical supervision. Available in reduced price blister packaging (5 x 10 capsules per box), this product offers significant savings with superior quality. Originating from India, TAKFA 0.5 is trusted by healthcare professionals worldwide.

Competitive Advantages and Commercial Usage

Tacrolimus Capsules IP stands out for its extraordinary effectiveness, particularly in the prophylaxis of organ rejection for adult kidney, liver, or heart transplant recipients. With an impeccable safety profile when used as recommended, its oral administration ensures ease of use. Commercially valuable, it is favored by healthcare institutions for its time-tested reliability and savings in post-transplant care. Its blister-packaged presentation makes it highly suitable for suppliers, exporters, and traders across pharmaceutical markets.

Main Export Markets, Payment & Shipment Terms

Tacrolimus Capsules IP is in high demand across major export markets including Asia, Africa, and Latin America. Valuation is competitive, allowing buyers to benefit from genuine savings without compromising quality. Transportation and shipment arrangements ensure timely delivery under secure conditions. Flexible payment terms can be negotiated based on order volume. Sample availability facilitates preliminary product evaluation prior to bulk purchase, continually attracting new clients and enhancing international trust.

FAQ's of Tacrolimus Capsules IP:

Q: How should Tacrolimus Capsules IP 0.5 mg be taken?

A: Tacrolimus Capsules IP 0.5 mg should be taken orally, exactly as directed by your physician. It is important not to exceed the recommended dose and to follow all dosage guidelines closely to ensure optimal efficacy and safety.

Q: What are the commercial benefits of choosing TAKFA 0.5 for organ transplant rejection prophylaxis?

A: TAKFA 0.5 offers verifiable reliability, competitive savings due to its reduced price, and an impeccable reputation for efficacy. Its packaging and shelf life also add value for exporters, suppliers, and traders.

Q: When is Tacrolimus therapy typically recommended?

A: Tacrolimus therapy is typically recommended for adults as part of the post-transplant regimen to prevent organ rejection after kidney, liver, or heart transplantation, as determined by a qualified physician.

Q: Where is TAKFA 0.5 manufactured and by whom is it marketed?

A: TAKFA 0.5 is manufactured and marketed in India by Intas Pharmaceuticals Ltd., known for their high-quality standards and venerable pharmaceutical experience.

Q: What is the process for ordering and receiving shipments internationally?

A: International orders can be processed through negotiations regarding payment terms and shipment schedules. Efficient transportation methods ensure timely and safe delivery. Sample products are often available for initial evaluation prior to bulk purchases.

Q: What are the possible side effects of Tacrolimus Capsules IP?

A: Possible side effects include increased risk of infection, kidney problems, and hypertension. It is recommended to use this medication only under strict medical supervision to manage potential risks effectively.

Tell us about your requirement